GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » EV-to-FCF

Kodiak Sciences (Kodiak Sciences) EV-to-FCF : 0.13 (As of Apr. 25, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kodiak Sciences's Enterprise Value is $-26.31 Mil. Kodiak Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-195.61 Mil. Therefore, Kodiak Sciences's EV-to-FCF for today is 0.13.

The historical rank and industry rank for Kodiak Sciences's EV-to-FCF or its related term are showing as below:

KOD' s EV-to-FCF Range Over the Past 10 Years
Min: -38.78   Med: 0   Max: 1.54
Current: 0.15

During the past 8 years, the highest EV-to-FCF of Kodiak Sciences was 1.54. The lowest was -38.78. And the median was 0.00.

KOD's EV-to-FCF is ranked better than
88.3% of 393 companies
in the Biotechnology industry
Industry Median: 4.27 vs KOD: 0.15

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Kodiak Sciences's stock price is $3.23. Kodiak Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.960. Therefore, Kodiak Sciences's PE Ratio for today is At Loss.


Kodiak Sciences EV-to-FCF Historical Data

The historical data trend for Kodiak Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences EV-to-FCF Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -72.28 -73.18 -15.24 0.06 0.23

Kodiak Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.04 -0.30 0.85 0.23

Competitive Comparison of Kodiak Sciences's EV-to-FCF

For the Biotechnology subindustry, Kodiak Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kodiak Sciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's EV-to-FCF falls into.



Kodiak Sciences EV-to-FCF Calculation

Kodiak Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-26.307/-195.61
=0.13

Kodiak Sciences's current Enterprise Value is $-26.31 Mil.
Kodiak Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-195.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kodiak Sciences  (NAS:KOD) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kodiak Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.23/-4.960
=At Loss

Kodiak Sciences's share price for today is $3.23.
Kodiak Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.960.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Kodiak Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Kodiak Sciences (Kodiak Sciences) Business Description

Traded in Other Exchanges
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Executives
Jason Ehrlich officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
John A. Borgeson officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth director, 10 percent owner, officer: Chairman, President and CEO 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang officer: See Remarks 2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek director P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016

Kodiak Sciences (Kodiak Sciences) Headlines

From GuruFocus